Investigative Ophthalmology & Visual Science · 2014 · 21 citations · 42 references
MedicineOphthalmologyVision ScienceClinical Vision ScienceOcular DiseaseOcular ImagingGlaucomaOptical Coherence TomographyRetinal ExaminationVision AssessmentVisual Field AssessmentVisual ImpairmentGlaucoma Visual Field AssessmentGlaucoma Visual Field TestingPopulation-based Eye Disease ScreeningSpectral-domain Optical Coherence TomographyVision ScreeningVisual Field ScreeningVisual Function LossVisual Function Measurement
PURPOSE: To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT). METHODS: Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs. RESULTS: Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program ("screen only") cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program ("screen and treat") had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813. CONCLUSIONS: Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program.
42
The Ocular Hypertension Treatment Study
Michael A. Kass · Archives of Ophthalmology · 2002 · 3.7K citations · Full text
Reduction of Intraocular Pressure and Glaucoma Progression
Anders Heijl · Archives of Ophthalmology · 2002 · 3.3K citations
Factors for Glaucoma Progression and the Effect of Treatment
M. Cristina Leske · Archives of Ophthalmology · 2003 · 2K citations
Medicine, Ophthalmology, Surgery +14
Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey
James M. Tielsch · JAMA · 1991 · 1.1K citations
Medicine, Ophthalmology, Surgery +11